Related references
Note: Only part of the references are listed.Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
Albert Jang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)
Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy
Anja Feldmann et al.
ONCOIMMUNOLOGY (2020)
Theranostic CAR T cell targeting: A brief review
Claudia Arndt et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2019)
The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells
Michael Bachmann
IMMUNOLOGY LETTERS (2019)
Conventional CARs versus modular CARs
Anja Feldmann et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR
Claudia Arndt et al.
ONCOIMMUNOLOGY (2019)
Past, Current, and Future of Immunotherapies for Prostate Cancer
Adeline N. Boettcher et al.
FRONTIERS IN ONCOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Preparation of 177Lu-labeled Nimotuzumab for radioimmunotherapy of EGFR-positive cancers: Comparison of DOTA and CHX-A-DTPA as bifunctional chelators
Usha Pandey et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2019)
Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study
Frederik L. Giesel et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Engrafting human regulatory T cells with a flexible modular chimeric [ antigen receptor technology
Stefanie Koristka et al.
JOURNAL OF AUTOIMMUNITY (2018)
PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter?
David Taieb et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Ga-68-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging
Christoph Rischpler et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo
Susann Albert et al.
Oncotarget (2018)
Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer
So Hee Dho et al.
SCIENTIFIC REPORTS (2018)
Improved Conjugation, 64-Cu Radiolabeling, in Vivo Stability, and Imaging Using Nonprotected Bifunctional Macrocyclic Ligands: Bis(Phosphinate) Cyclam (BPC) Chelators
Tomas David et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Pitfalls in Gallium-68 PSMA PET/CT Interpretation-A Pictorial Review
Deepa Shetty et al.
TOMOGRAPHY (2018)
177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
Axel Braeuer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Pretargeted Imaging and Therapy
Mohamed Altai et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
The context of prostate cancer genomics in personalized medicine
Yanling Liu
ONCOLOGY LETTERS (2017)
Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression
Theresa Link et al.
ONCOTARGET (2017)
177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
Finn E. von Eyben et al.
ONCOTARGET (2017)
Retargeting of T lymphocytes to PSCA-or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology UniCAR
Anja Feldmann et al.
ONCOTARGET (2017)
Gallium-68 PSMA uptake in adrenal adenoma
W. Phillip Law et al.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2016)
New insights into the pretargeting approach to image and treat tumours
Malay Patra et al.
CHEMICAL SOCIETY REVIEWS (2016)
Follicular Thyroid Adenoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT
Gowri L. Kanthan et al.
CLINICAL NUCLEAR MEDICINE (2016)
Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
Kambiz Rahbar et al.
CLINICAL NUCLEAR MEDICINE (2016)
90Y/177Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation
Rubel Chakravarty et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2016)
Molecular Imaging of Prostate Cancer
Andreas G. Wibmer et al.
RADIOGRAPHICS (2016)
High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe
Thilo Riedl et al.
JOURNAL OF BIOMOLECULAR SCREENING (2016)
Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
Matthias Eiber et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Evolving Important Role of Lutetium-177 for Therapeutic Nuclear Medicine
Ambikalmajan M. R. Pillai et al.
CURRENT RADIOPHARMACEUTICALS (2015)
Radiation Dosimetry Aspects of Lu-177
Michael Lassmann et al.
CURRENT RADIOPHARMACEUTICALS (2015)
Uptake of [18F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies
Steven P. Rowe et al.
TOMOGRAPHY (2015)
A Novel Ex Vivo Isolation and Expansion Procedure for Chimeric Antigen Receptor Engrafted Human T Cells
Marc Cartellieri et al.
PLOS ONE (2014)
Simultaneous Targeting of Prostate Stem Cell Antigen and Prostate-Specific Membrane Antigen Improves the Killing of Prostate Cancer Cells Using a Novel Modular T Cell-Retargeting System
Claudia Arndt et al.
PROSTATE (2014)
Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
Matthias Eder et al.
PHARMACEUTICALS (2014)
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
A. Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B
Stefanie Koristka et al.
JOURNAL OF AUTOIMMUNITY (2013)
Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells
Anja Feldmann et al.
JOURNAL OF IMMUNOLOGY (2012)
MRI of Prostate Cancer Antigen Expression for Diagnosis and Immunotherapy
Jing Ren et al.
PLOS ONE (2012)
Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer
Andrea Kiessling et al.
Cancers (2012)
Retargeting of T Cells to Prostate Stem Cell Antigen Expressing Tumor Cells: Comparison of Different Antibody Formats
Anja Feldmann et al.
PROSTATE (2011)
PET/CT Imaging and Radioimmunotherapy of Prostate Cancer
Kirsten Bouchelouche et al.
SEMINARS IN NUCLEAR MEDICINE (2011)
Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands
Marc Hens et al.
NUCLEAR MEDICINE AND BIOLOGY (2010)
Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis
Sebastian Mannweiler et al.
PATHOLOGY & ONCOLOGY RESEARCH (2009)
Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells
Agnieszka Morgenroth et al.
PROSTATE (2007)
Imaging prostate cancer: A multidisciplinary perspective
Hedvig Hricak et al.
RADIOLOGY (2007)
Lu-177-labeled-VG76e monoclonal antibody in tumor angiogenesis: A comparative study using DOTA and DTPA chelating systems
M. Fani et al.
RADIOCHIMICA ACTA (2007)
In vitro and in vivo characterization of 177Lu-huA33 A radioimmunoconjugate against colorectal cancer
Ylva Almqvist et al.
NUCLEAR MEDICINE AND BIOLOGY (2006)
Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues
Ana C. Cunha et al.
CANCER LETTERS (2006)
[177Lu]pertuzumab:: experimental studies on targeting of HER-2 positive tumour cells
M Persson et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism
ZN Gu et al.
CANCER RESEARCH (2005)
Prostate stem cell antigen is overexpressed in prostate cancer metastases
JS Lam et al.
CLINICAL CANCER RESEARCH (2005)
Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer
KR Han et al.
JOURNAL OF UROLOGY (2004)
Antibody-targeted radiation cancer therapy
DE Milenic et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity
WAP Breeman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts
DC Saffran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer
Z Gu et al.
ONCOGENE (2000)
Share Paper
